Collaboration, License, and Other Agreements - Sanofi, Immuno-Oncology Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator	$ 3,362.7	$ 2,936.2		$ 9,682.9	$ 8,758.5
Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to collaborating party			$ 900.0
Sanofi Collaboration Agreement, Immuno-oncology
Disaggregation of Revenue [Line Items]
Royalty payment to collaborating party, percentage of net product sales				11.00%
Sanofi Collaboration Agreement, Immuno-oncology | Regulatory Milestone | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to collaborating party			100.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestones | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator			100.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestone One | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator			$ 65.0
Sanofi Collaboration Agreement, Immuno-oncology | Sales-Based Milestone Two | Sanofi
Disaggregation of Revenue [Line Items]
Up-front payment to be made to collaborator				$ 35.0